We then evaluated the primary moderation hypothesis, by combining genetic status (AGES) and treatment in an interaction term and examined the relationship with smoking lapse risk and PPA-EOT. The relationship between the interaction term (AGES × drug) and risk for smoking lapse is depicted in Figure 1 along with shaded regions indicating 95% confidence limits. Participants with lower AGES had similar risk of lapse whether they received placebo or active drug treatment. However, as AGES increased, the risk of lapse increased in a linear fashion for those receiving placebo. Those participants with the highest AGES have the highest risk of smoking lapse on placebo when compared to active drug. We did not observe a significant moderating effect of AGES with PPA-EOT (p<0.22). When evaluating the odds of being abstinent at the end of treatment those participants with varying levels of AGES scores had similar odds of abstinence in line with the effects of active or placebo treatment received. We explored potential interaction of AGES with gender and FTND. When added as a set, neither of these interaction terms of AGES
